ArticleIn vivo (Athens, Greece)
Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimImmune checkpoint inhibitors are widely used in treating metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, the incidence, timing, and clinical impact of immune-related adverse events in real-world practice remain unclear. This study aimed to investigate their onset patterns and outcomes. PATIENTS AND
methodsWe retrospectively analyzed 210 patients with metastatic urothelial carcinoma (n=127) or metastatic renal cell carcinoma (n=83) treated with immune checkpoint inhibitors between 2017 and 2023 at a single academic institution. Events were graded using Common Terminology Criteria for Adverse Events version 5.0. Associations with progression-free and overall survival were assessed. We also evaluated cumulative incidence, corticosteroid or immunosuppressant use, and outcomes after rechallenge.
resultsImmune-related adverse events occurred in 78 patients (37.1%), more frequently in metastatic renal cell carcinoma (47.0%) than in metastatic urothelial carcinoma (30.9%). Overall, grade ≥3 events occurred in 22.0% of patients, with higher incidence in renal cell carcinoma (27.7%) than in urothelial carcinoma (17.3%). In metastatic urothelial carcinoma, their presence was linked to longer survival; no difference was seen in metastatic renal cell carcinoma. Most events developed within six months; only 3.4% occurred after one year. High-dose corticosteroids were administered in 13.8% of patients, and 72.4% of them successfully completed tapering. Immunosuppressants were used in 1.4%. Eleven patients underwent rechallenge, of whom two experienced recurrence.
conclusionImmune-related adverse events showed distinct incidence and prognostic relevance between urothelial and renal cell carcinoma. These findings underscore the need for treatment-specific monitoring and provide practical insights into managing toxicities and decisions regarding immunotherapy rechallenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.